P

Pfizer

Biopharmaceutical company develops medicines and vaccines

Directory Services Senior Manager - Directory Engineer

Full-TimePosted on 8/13/2026Deadline 9/5/26
$124.4k - $207.4k/yr+ 17.5% bonus target + Share-based long-term incentive
Senior
Bachelor's, Master's
Collegeville, PA, USA+1 moreMore locations: New York, NY, USA
HybridHybrid schedule requires working from the assigned office 2–3 days per week. Periodic international and domestic travel is required.
System Administration, IT Operations
No H1B Sponsorship

About the job

Requirements
  • Bachelor’s degree in a relevant discipline.
  • At least 6 years of experience in identity and access management, including at least 4 years focused on directory solutions supporting directories with more than 50,000 users.
  • Strong background in information technology security, authentication protocols, and identity and access management frameworks supporting directories.
  • Deep understanding of directory technologies, including LDAP/LDAPS, directory schema, replication, and Group Policy Objects, and experience with Public Key Infrastructure solutions.
  • Knowledge of identity providers including Microsoft Active Directory, Active Directory Lightweight Directory Services, and Azure Active Directory.
  • Ability to solve highly complex authentication and authorization problems in a global environment.
  • Strong understanding of security best practices related to identity management, including encryption, tokenization, and secure protocols.
  • Experience leading identity and access management system support, engineering, and operations teams within a global business unit.
  • Understanding of applicable laws and regulations, including Sarbanes-Oxley and GXP quality regulations and guidelines.
  • Ability to hold relevant stakeholders and project teams accountable, with a proven track record of successfully managing and executing long-term complex projects.
  • Demonstrated experience in an agile work environment, with a collaborative mindset, adaptability to change, and a proactive problem-solving approach.
  • Candidates must be authorized to be employed in the United States by any employer.
  • The position requires permanent work authorization in the United States.
Responsibilities
  • Develop and execute the enterprise directory services roadmap to ensure secure and user-friendly access across enterprise applications and platforms.
  • Modernize legacy directory infrastructure.
  • Establish standards for directory design and governance while ensuring scalability, resiliency, and high availability.
  • Lead directory consolidation and migration initiatives.
  • Oversee the design, implementation, and ongoing optimization of directory services.
  • Ensure directory services are scalable, resilient, and integrated with internal and third-party services.
  • Work closely with information technology, security, development, and product teams to integrate directory capabilities into new and existing platforms.
  • Provide guidance on best practices for secure access management.
  • Maintain understanding of security protocols and compliance standards, including GDPR, HIPAA, and NIST, and ensure directory solutions align with relevant regulations and industry standards.
  • Lead the development and implementation of security controls related to authentication and authorization.
  • Manage relationships with vendors and third-party providers, ensuring successful product implementation and ongoing support.
  • Lead the team in investigating and resolving issues related to directory functionality.
  • Ensure incidents are managed efficiently and improvements are implemented to minimize future disruptions.
  • Ensure directory implementation improves the end-user experience by simplifying login processes while maintaining high-security standards.
  • Work on reducing friction points and increasing user adoption.
  • Help develop key performance indicators for directory performance and security metrics.
  • Regularly report on directory effectiveness, user engagement, security breaches, and other relevant metrics.
  • Develop and coach others and oversee and guide colleagues' work to achieve meaningful outcomes.
Desired Qualifications
  • Master’s degree in a relevant discipline.
  • Deep expertise in Microsoft solutions.

About the company

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $15.0 billion, and management raised full-year guidance to $60.5-$62.5 billion.
  • FDA approved Pfizer's 2026-2027 XFG Comirnaty vaccine on August 28, 2026.
  • Innovent and Metsera expand Pfizer's pipeline, while non-COVID revenue grew 5% operationally in Q2.

What critics are saying

  • Eliquis loses protection by 2028, and Ibrance faces U.S. patent expiry in 2027.
  • Pfizer just cut MET-224o and PF-07976016, proving obesity execution remains fragile versus Lilly.
  • Sanofi, Arbutus, and Bayer lawsuits target mRNA and LNP royalties, while restructuring runs through 2029.

What makes Pfizer unique

  • Pfizer spans vaccines, oncology, and cardiometabolic drugs across 2026, unlike narrower peers.
  • Metsera gave Pfizer monthly GLP-1 and amylin assets, plus obesity scale overnight.
  • Its global manufacturing and distribution network keeps Comirnaty, Padcev, and Vyndaqel commercially resilient.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -4%

1 year growth

↓ -3%

2 year growth

↓ -3%
Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.

Business Wire
Oct 7th, 2026
Pfizer's TUKYSA wins FDA approval for front-line HER2+ metastatic breast cancer maintenance treatment

The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.

Yahoo Finance
Oct 7th, 2026
Buffett indicator hits 235.8% as Oracle warns investors 'playing with fire' — 3 undervalued stocks to buy

Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.

Yahoo Finance
Oct 6th, 2026
Vaxcyte's VAX-31 vaccine matches Pfizer's $6.49B Prevnar on all serotypes in Phase 3 trial

Vaxcyte announced its 31-valent pneumococcal vaccine, VAX-31, met all primary endpoints in a Phase 3 trial with 4,047 participants. The vaccine matched Pfizer's Prevnar 20 on all 20 shared serotypes and Merck's Capvaxive on 17 of 19 shared serotypes. Pfizer's Prevnar franchise generated $6.49 billion in 2025, representing roughly 10% of the company's $62.58 billion total revenue. The franchise grew just 1% last year, with Pfizer citing lower US market share. Merck's Capvaxive brought in $759 million in 2025, about 1% of its revenue. Pfizer trades at 9.87x forward earnings whilst Merck trades at 16.36x. Vaxcyte plans to file for approval in the first half of 2028. The company expects results from two additional trials in the first half of 2027.

Yahoo Finance
Sep 24th, 2026
Bristol Myers Squibb vs Pfizer: which healthcare stock is a better buy in 2026?

Bristol Myers Squibb and Pfizer, two pharmaceutical giants facing patent cliffs on blockbuster drugs, are taking divergent approaches to growth. Bristol Myers focuses on oncology and immunology whilst Pfizer leverages pandemic-era cash for acquisitions in high-growth areas like obesity treatments. Bristol Myers reported FY 2025 revenue of $48.2 billion, down 0.2% year-over-year, with net income of $7.1 billion and a 14.6% net margin. The company maintains a debt-to-equity ratio of 2.6x and generated $12.8 billion in free cash flow. Pfizer's FY 2025 revenue totalled $62.6 billion, declining 1.6%, with net income of $7.8 billion and a 12.4% net margin. Recent acquisitions include Seagen and Metsera, positioning the firm in oncology and obesity markets. Both companies partner with distributors and maintain global operations across multiple therapeutic areas.

INACTIVE